Our new ad campaign highlights why American patients pay more for prescription medicines than anywhere else: the U.S. lets PBMs, large hospitals and insurers drive up prices for patients while other countries don’t pay their fair share. It’s time to rein in middlemen and end

Tackling chronic disease requires a comprehensive strategy that focuses on prevention and early intervention, health and wellness, and the development of new treatments and cures. Our CMO, @mybarra, shares how medicines can prevent disease and disease progression, helping to

The 340B hospital markup program and PBMs are increasing patient costs in the U.S., marking up medicines by as much as 1000% or more. To lower drug costs in America, policymakers must hold drug middlemen accountable.

Foreign first pricing schemes don’t address the real reasons Americans pay more for prescription drugs. If policymakers want to lower drug costs in the U.S. they must rein in PBMs, fix the 340B hospital markup program and crack down on foreign governments not paying their fair.

RT @steveubl: Congratulations to @GSK's Emma Walmsley, @Novartis's @VasNarasimhan and @EliLillyandCo's David Ricks for being recognized o….

New technologies like artificial intelligence hold great promise to improve the efficiency of new medicine development and help us fight disease sooner. Learn more about how AI is transforming R&D:

RT @steveubl: To lower costs for Americans, we need to address the real reasons U.S. prices are higher: foreign countries not paying their….

This week, 28 biopharmaceutical researchers representing 16 companies met with 63 CA lawmakers to champion the importance of innovation and policies that support the development of life-saving medical breakthroughs. #CaLeg #CAInnovation. @biogen @pfizer @genentech @bmsnews

.@GileadSciences' increased U.S. presence won’t just foster scientific innovation – it also supports an industry-wide effort to invest in U.S. manufacturing, strengthen the American economy and create high-quality jobs. Investments like this are only possible with smart.

Big tax-exempt hospitals abuse a little-known federal program to charge huge markups on medicines to boost their profits – passing the bill to patients. Congress should fix 340B.

The biopharmaceutical industry invests significant amounts into R&D to drive the next generation of treatments. Patents fuel these investments and incentivize innovation. Our policy landscape must continue to support our IP system. Learn more:

Advances in immunology have revolutionized the field of oncology, offering hope to cancer patients across the country. This progress was made possible by American leadership in biopharmaceuticals and a predictable policy environment. Learn more:

The IRA’s price-setting policies and PBM efforts to block biosimilar competition jeopardize the market's progress in increasing patients’ treatment options. Our VP of Policy and Research, @jocelynulrich, recently discussed alongside @Amgen how we can protect this vital market.

We need to address how PBMs and insurers are driving up costs for patients. Our CMO, Mike Ybarra, shared his thoughts at a recent Reuters events forum. #REpharmaUSA

This #MentalHealthAwarenessMonth, protecting access to mental health treatment must be a priority. The pill penalty is putting that access at risk—discouraging the development of affordable, at-home medications that are essential in treating mental health disorders.

Because of the pill penalty, patients lose. This misguided policy discourages the development of affordable, at-home medicines by allowing price setting years earlier than other drugs. More on @VitalTransform’s new study:.

New study: From 2012–2022, #Biopharma contributed more wages, exports, output and GDP per employee than most other U.S. manufacturing industries. A powerhouse driving America's economy and innovation! . More here:

RT @mybarra: We’re celebrating #WorldImmunizationWeek this week and taking a moment to recognize just how powerful vaccines are. They save….